Payment overview · 2025
General Payments
$311.70
15 reported records · 8 companies
Healthcare provider profile · identity verified
Thomas Perkins, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PRAIRIEVILLE, LA · NPI 1508859042
Verified facts
What the public records show
CMS Open Payments records show Thomas Perkins, M.D. received $311.70 in general payments during 2025 across 15 reported records.
Axsome Therapeutics, Inc. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.24 | 20.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $59.54 | 19.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.45 | 17.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.76 | 12.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.81 | 10.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.72 | 8.6% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $21.84 | 7.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.34 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.70 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $62.24 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $59.54 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 580 | 179 |
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 154 |
| Lisinopril | Lisinopril | 364 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 82 |
| Ezetimibe | Ezetimibe | 265 | 87 |
| Metformin Hcl | Metformin Hcl | 264 | 85 |
| Metformin Hcl Er | Metformin Hcl | 240 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 206 | 63 |
| Omeprazole | Omeprazole | 193 | 56 |
| Alprazolam | Alprazolam | 192 | 32 |
| Losartan Potassium | Losartan Potassium | 174 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 55 |
| Gabapentin | Gabapentin | 150 | 58 |
| Sertraline Hcl | Sertraline Hcl | 142 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 37 |
| Trazodone Hcl | Trazodone Hcl | 113 | 32 |
| Cefdinir | Cefdinir | 110 | 93 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 29 |
| Potassium Chloride | Potassium Chloride | 98 | 30 |
| Famotidine | Famotidine | 95 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 30 |
| Ozempic | Semaglutide | 94 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 32 |
| Bupropion Xl | Bupropion Hcl | 91 | 28 |
| Clonazepam | Clonazepam | 90 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 27 |
| Montelukast Sodium | Montelukast Sodium | 89 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 29 |
| Ramipril | Ramipril | 81 | 26 |
| Buspirone Hcl | Buspirone Hcl | 76 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 20 |
| Glimepiride | Glimepiride | 69 | 26 |
| Chlorthalidone | Chlorthalidone | 67 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 19 |
| Mounjaro | Tirzepatide | 63 | 16 |
| Simvastatin | Simvastatin | 59 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 16 |
| Carvedilol | Carvedilol | 52 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 16 |
| Synthroid | Levothyroxine Sodium | 50 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 14 |
| Eliquis | Apixaban | 48 | 11 |
| Azithromycin | Azithromycin | 47 | 40 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 11 |
| Mirtazapine | Mirtazapine | 46 | 14 |
| Cephalexin | Cephalexin | 43 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 15 |
| Mupirocin | Mupirocin | 43 | 38 |
| Furosemide | Furosemide | 42 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Atenolol | Atenolol | 38 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 14 |
| Meloxicam | Meloxicam | 38 | 14 |
| Allopurinol | Allopurinol | 36 | 14 |
| Valsartan | Valsartan | 36 | 12 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | 11 |
| Meclizine Hcl | Meclizine Hcl | 32 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 14 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Olanzapine | Olanzapine | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 15 |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Jardiance | Empagliflozin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.70 · 15 records | Axsome Therapeutics, Inc. | Auvelity, COMIRNATY, FREESTYLE LIBRE 3, JARDIANCE, Natroba, OTEZLA, PAXLOVID, PENBRAYA, PREVNAR 20, REPATHA, Spinosad, TRINTELLIX, TRUMENBA, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error